Jeffrey L. Wade has been executive vice president and general counsel of Lexicon Pharmaceuticals, Inc. since February 2000 and was Lexicon’s senior vice president and chief financial officer from January 1999 to February 2000. During his tenure with the company and as its counsel, Mr. Wade has played an instrumental role in completing securities offerings for the company totaling more than $560 million, including its $220 million initial public offering in April 2000 and a $205 million private equity financing in August 2007; completing the acquisition that established the basis for the company’s small molecule drug discovery efforts; and negotiating collaborations and licenses involving more than $450 million in committed funding to the company, including strategic alliances with Bristol-Myers Squibb Company, Genentech, Inc, N.V. Organon and Takeda Pharmaceutical Company Limited, among others, and a product financing collaboration with a group of investors led by Symphony Capital, L.P.  Before joining Lexicon, Mr. Wade was a partner with the law firm of Andrews & Kurth L.L.P., where he represented companies in the biotechnology, information technology and energy industries, as well as venture capital and investment banking firms. His practice at the firm consisted primarily of corporate finance and securities transactions, including public offerings, strategic alliances and joint ventures, mergers and acquisitions and venture capital financings.  Mr. Wade is a member of the boards of directors of the Texas Healthcare and Bioscience Institute and also serves as a member of the Texas Governor's Competitiveness Council. Mr. Wade received his B.A. (Plan II) and J.D. from The University of Texas.